The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Providers and lawmakers fear that payments for some federally funded health programs aren’t being dispersed amid confusing federal guidance.

Sales for our core business were up 4% CER when excluding ... securing partnership with Eli Lilly in Alzheimer’s disease or AstraZeneca in chronic diseases. Looking ahead in 2025 and beyond ...

But it's in core functional areas, finance in terms of expense management ... One of the other themes that came up in that conversation and also with Eli Lilly CEO Dave Ricks, was really about the ...

For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...

Eli Lilly expands its partnership with AdvanCell to advance targeted alpha therapies using Pb-212 technology for cancer treatment. Lilly inks a global licensing deal with OliX for OLX75016 ...

On Monday, Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated steatohepatitis (MASH), respectively. AdvanCell announced that it ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...